BioLineRx readies celiac disease trial in Finland

|About: BioLineRx Ltd. (BLRX)|By:, SA News Editor

BioLineRx (BLRX +0.5%) files to commence a Phase 1/2 trial in Finland for the celiac disease treatment BL-7010.

The study will evaluate the safety of single and repeated doses in well-controlled celiac patients.

Finland has a "significantly higher prevalence of celiac disease than other countries," CEO Kinneret Savitsky notes.

The study should commence in Q4. (PR)